Outro Raises $7M to Expand Antidepressant Tapering Care

Deciding a medication may have finished its job can begin another stretch of care. Outro Health is building a business around that stretch, providing clinician-supervised antidepressant tapering for people whose treatment decisions require follow-up, adjustment and someone available when the original plan needs to change.

The New York company announced $7M across pre-seed and seed rounds on October 8, 2026. Co-founder and CEO Brandon Goode and co-founder Dr. Mark Horowitz are putting the capital toward a larger clinician network and a broader deprescribing platform. The financing supports a specialized care model in which continuing clinical attention is part of what the patient buys.

What Outro's $7M announcement covers

Outro named Listen Ventures, Cake Ventures, LAUNCH, Actions Capital, Hannah Grey VC, SemperVirens, Brock Recovery Group and Pave Health Ventures among its investors. The company presented $7M as capital across two early stages. It did not disclose the split between pre-seed and seed, identify a lead investor or provide individual closing dates and a valuation.

That accounting matters for understanding the company's position. Combining the two stages into one headline is reasonable; describing the announcement as a single newly closed $7M seed round would create a transaction the source did not report. The release also leaves readers without enough information to calculate ownership, runway or the amount available for each expansion priority.

Outro says the money will grow its clinician network, support AI applications for deprescribing workflows, extend its model into additional drug classes and deepen university and advocacy partnerships. Each item describes work ahead. The announcement supplies no basis for treating AI as an autonomous prescriber or for assigning launch dates to the additional programs.

Listen's Ellen Wilcox, whose official biography identifies her as Partner and Head of Listening, framed the investment around patients seeking more choice and clinical guidance. That investor perspective helps explain the commercial thesis: a patient's wish to revisit medication can create demand for a distinct service with continuing responsibility attached.

The founders followed a problem across treatment settings

Brandon Goode described the formative observation in an April 2026 interview with Amy Kruse. Working in interventional psychiatry and ketamine care, he encountered people whose immediate concern was difficulty stopping an antidepressant they had already taken for years. Exploring new treatments had brought him into contact with an unresolved problem around existing treatment.

Goode's account places the company inside a practical patient decision rather than an abstract technology opportunity. A service built around that decision has to understand medication history, previous attempts and the reasons someone is considering a change. Those are inputs to a clinical relationship, with consequences that extend beyond whether an application is easy to use.

Mark Horowitz brings research into antidepressant withdrawal and tapering to the company. Outro's current leadership page also describes his own difficult experience discontinuing an antidepressant. The connection between research and lived experience is part of Outro's origin; it should not be mistaken for independent proof of the service's outcomes.

A 2023 interview with the founding team identifies Tyler Dyck and Adele Framer alongside Goode and Horowitz in the company's formation. The current official site lists Framer as an advisor and does not establish Dyck's present operating role. Keeping that history intact gives the patient advocacy and operational contributions their place without assigning anyone an unsupported executive title.

What the patient relationship requires

Outro describes a program combining individualized tapering plans, clinical visits, symptom monitoring, psychosocial support and access to custom prescriptions. The company reports availability in 14 U.S. states. Its current pricing page lists the program at $225/month, a useful reference point for a service whose duration can vary with the patient.

The company's methodology page describes hyperbolic tapering, with progressively smaller dose reductions toward the lower end of a taper. That description explains why formulation options and adjustments can matter to the service. It does not supply a universal timetable, a patient-specific recommendation or a guarantee that a particular individual will avoid withdrawal.

Independent clinical guidance supports the need for ongoing judgment. NICE's depression guideline recommends agreed, staged reduction and monitoring for withdrawal and returning depression symptoms. Its guidance recognizes that withdrawal may take weeks or months, with the pace determined by clinical circumstances and the person's response. NICE's recommendations establish a clinical context, rather than an endorsement of Outro.

The operating implication is that an initial plan cannot carry the entire customer experience. A clinician needs information when symptoms change, a way to assess what they mean and a workable route to the next adjustment. Coordination across visits, communication and medication access makes continuity a concrete part of delivery. The company has not disclosed patient enrollment, revenue or independently validated outcome data in the funding announcement, leaving the scale and economics of that delivery open.

Building capacity around a changing plan

Outro's expansion priorities put clinical capacity beside software development. A larger network can increase access, while workflow tools may help the care team organize information and follow-up. The announcement leaves the precise AI implementation unspecified, so its value has to be understood as a planned operational investment rather than an established clinical capability.

For investors and health operators, the relevant question is how a specialist service carries responsibility as its patient base grows. The listed monthly price makes duration commercially meaningful, but the public record does not establish margins, clinician utilization or reimbursement coverage. Those missing details matter to the business model without changing the verified funding event.

Elsewhere in healthcare, DevCuration's coverage of General Medicine's care marketplace and AblePay's patient-payment model examines different parts of the work around receiving care. Outro's contribution sits in clinical follow-through when a treatment plan changes. These are adjacent operating problems, not evidence that the companies share a product, partnership or competitive relationship.

Outro now has capital earmarked for a wider network and additional services. Inside that expansion, the patient still needs a clinician who knows the history, receives the next update and can revise the plan without making the relationship start over. That continuing responsibility will travel with every new state and medication class the company chooses to serve.